3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Other
1
Myeloid
1
Lymphoid
1
Conditions
Unspecified Adult Solid Tumor, Protocol Specific
1
Primary Myelofibrosis
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Myelodysplastic Syndromes
1
Mucositis
1
Lymphoma, Non-Hodgkin
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hodgkin Disease
1
Interventions
Azacitidine
56
Cyclophosphamide
44
fludarabine phosphate
42
fludarabine
37
Decitabine
27
venetoclax
26
Cytarabine
25
Tacrolimus
20
Specimen Handling
18
Filgrastim
18
Busulfan
18
Melphalan
17
Whole-Body Irradiation
16
Mycophenolic Acid
16
Antilymphocyte Serum
14
Granulocyte Colony-Stimulating Factor
12
Clofarabine
12
Biopsy
12
Peripheral Blood Stem Cell Transplantation
11
Injections
11
Etoposide
11
Methotrexate
10
thymoglobulin
9
Thiotepa
9
Stem Cell Transplantation
9
Lenalidomide
9
decitabine and cedazuridine drug combination
8
aldesleukin
8
Sirolimus
8
Nivolumab
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 1
×
Myelodysplastic Syndromes
×
angiotensin I (1-7)
×
Clear all
NCT01300611
2020-12-08
USBTXA127CBT
Tarix Pharmaceuticals
Phase 1
Terminated
20 enrolled